Generic Bepreve Availability

Bepreve is a brand name of bepotastine ophthalmic, approved by the FDA in the following formulation(s):

BEPREVE (bepotastine besilate - solution/drops;ophthalmic)

  • Manufacturer: BAUSCH AND LOMB INC
    Approval date: September 8, 2009
    Strength(s): 1.5% [RLD]

Has a generic version of Bepreve been approved?

No. There is currently no therapeutically equivalent version of Bepreve available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bepreve. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Acid addition salt of optically active piperidine compound and process for preparing the same
    Patent 6,780,877
    Issued: August 24, 2004
    Inventor(s): Jun-ichiro; Kita & Hiroshi; Fujiwara & Shinji; Takamura
    Assignee(s): Ube Industries, Ltd. Tanabe Seiyaku Co., Ltd.
    The present invention is to provide a benzenesulfonic acid salt and a benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid represented by the formula (I): wherein * represents an asymmetric carbon, which are excellent in antihistaminic activity and anti-allergic activity, and a process for producing the same.
    Patent expiration dates:
    • September 19, 2019
      Drug substance
      Drug product
  • Aqueous liquid preparations and light-stabilized aqueous liquid preparations
    Patent 8,784,789
    Issued: July 22, 2014
    Assignee(s): Senju Pharmaceutical Co., Ltd.
    An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.
    Patent expiration dates:
    • September 5, 2024
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 8, 2014 -


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.